

References for Products 5100 to 5109

1. Cadicamo CD, Asante V, Abu Ammar M, Borelli C, Korting HC, Kokschi B. (2009) Investigation of the synthetic route to pepstatin analogues by SPPS using O-protected and O-unprotected statine as building blocks. *J Pept Sci*, 15, 272.
2. Lazebnik LB, Zvenigorodskaja LA, Khomeriki SG, Efremov LI, Cherkashova EA. (2009) [Drug (statine)-induced hepatitis]. *Eksp Klin Gastroenterol*, 110.
3. Back M, Nyhlen J, Kvarnstrom I, Appelgren S, Borkakoti N, Jansson K, Lindberg J, Nystrom S, Hallberg A, Rosenquist S, Samuelsson B. (2008) Design, synthesis and SAR of potent statine-based BACE-1 inhibitors: exploration of P1 phenoxy and benzyloxy residues. *Bioorg Med Chem*, 16, 9471.
4. Preciado A, Williams PG. (2008) A simple microscale method for determining the relative stereochemistry of statine units. *J Org Chem*, 73, 9228.
5. Romeo S, Parapini S, Dell'Agli M, Vaiana N, Magrone P, Galli G, Sparatore A, Taramelli D, Bosisio E. (2008) Atovaquone-statine "double-drugs" with high antiplasmodial activity. *ChemMedChem*, 3, 418.
6. Barazza A, Gotz M, Cadamuro SA, Goettig P, Willem M, Steuber H, Kohler T, Jestel A, Reinemer P, Renner C, Bode W, Moroder L. (2007) Macrocyclic statine-based inhibitors of BACE-1. *Chembiochem*, 8, 2078.
7. Farran D, Toupet L, Martinez J, Dewynter G. (2007) Stereocontrolled synthesis of 2,4-diamino-3-hydroxyacids starting from diketopiperazines: a new route for the preparation of statine analogues. *Org Lett*, 9, 4833.
8. Bridges KG, Chopra R, Lin L, Svenson K, Tam A, Jin G, Cowling R, Lovering F, Akopian TN, DiBlasio-Smith E, Annis-Freeman B, Marvell TH, LaVallie ER, Zollner RS, Bard J, Somers WS, Stahl ML, Kriz RW. (2006) A novel approach to identifying beta-secretase inhibitors: bis-statine peptide mimetics discovered using structure and spot synthesis. *Peptides*, 27, 1877.
9. Zuo Z, Luo X, Zhu W, Shen J, Shen X, Jiang H, Chen K. (2005) Molecular docking and 3D-QSAR studies on the binding mechanism of statine-based peptidomimetics with beta-secretase. *Bioorg Med Chem*, 13, 2121.
10. Hu B, Fan KY, Bridges K, Chopra R, Lovering F, Cole D, Zhou P, Ellingboe J, Jin G, Cowling R, Bard J. (2004) Synthesis and SAR of bis-statine based peptides as BACE 1 inhibitors. *Bioorg Med Chem Lett*, 14, 3457.
11. Johansson PO, Chen Y, Belfrage AK, Blackman MJ, Kvarnstrom I, Jansson K, Vrang L, Hamelink E, Hallberg A, Rosenquist A, Samuelsson B. (2004) Design and synthesis of potent inhibitors of the malaria aspartyl proteases plasmepsin I and II. Use of solid-phase synthesis to explore novel statine motifs. *J Med Chem*, 47, 3353.
12. Romeo S, Dell'Agli M, Parapini S, Rizzi L, Galli G, Mondani M, Sparatore A, Taramelli D, Bosisio E. (2004) Plasmepsin II inhibition and antiplasmodial activity of Primaquine-Statine 'double-drugs'. *Bioorg Med Chem Lett*, 14, 2931.
13. Dahlgren A, Kvarnstrom I, Vrang L, Hamelink E, Hallberg A, Rosenquist A, Samuelsson B. (2003) Solid-phase library synthesis of reversed-statine type inhibitors of the malarial aspartyl proteases plasmepsin I and II. *Bioorg Med Chem*, 11, 827.
14. Finsterer J. (2003) [Fibrate and statine myopathy]. *Nervenarzt*, 74, 115.
15. Hom RK, Fang LY, Mamo S, Tung JS, Guinn AC, Walker DE, Davis DL, Gailunas AF, Thorsett ED, Sinha S, Knops JE, Jewett NE, Anderson JP, John V. (2003) Design and synthesis of statine-based cell-permeable peptidomimetic inhibitors of human beta-secretase. *J Med Chem*, 46, 1799.
16. Hu J, Cwi CL, Smiley DL, Timm D, Erickson JA, McGee JE, Yang HC, Mendel D, May PC, Shapiro M, McCarthy JR. (2003) Design and synthesis of statine-containing BACE inhibitors. *Bioorg Med Chem Lett*, 13, 4335.
17. Ko SY. (2002) Unusual regioselection in the Mitsunobu reactions of syn-2,3-dihydroxy esters: synthesis of statine and its diastereomer. *J Org Chem*, 67, 2689.
18. Rosati E, Aracri N, Bottone A, Cau C, Scotti E. (2002) [Statine and endothelium dysfunction in diabetes]. *Minerva Cardioangiol*, 50, 63.

19. Yoo D, Oh JS, Kim YG. (2002) The N-hydroxymethyl group for stereoselective conjugate addition: application to the synthesis of (-)-statine. *Org Lett*, 4, 1213.
20. Marcinkeviciene J, Luo Y, Graciani NR, Combs AP, Copeland RA. (2001) Mechanism of Inhibition of beta-site amyloid precursor protein-cleaving enzyme (BACE) by a statine-based peptide. *J Biol Chem*, 276, 23790.
21. Notarbartolo A, Barbagallo CM. (2001) [Characteristics of a statine of the most recent generation]. *Ital Heart J Suppl*, 2, 230.
22. Pesenti C, Bravo P, Corradi E, Frigerio M, Meille SV, Panzeri W, Viani F, Zanda M. (2001) Synthesis of (+)- and (-)-statine via chiral sulfoxide chemistry. *J Org Chem*, 66, 5637.
23. Bessodes M, Antonakis K, Herscovici J, Garcia M, Rochefort H, Capony F, Lelievre Y, Scherman D. (1999) Inhibition of cathepsin D by tripeptides containing statine analogs. *Biochem Pharmacol*, 58, 329.
24. Carroll CD, Johnson TO, Tao S, Lauri G, Orlowski M, Gluzman IY, Goldberg DE, Dolle RE. (1998) Evaluation of a structure-based statine cyclic diamino amide encoded combinatorial library against plasmepsin II and cathepsin D. *Bioorg Med Chem Lett*, 8, 3203.
25. Carroll CD, Patel H, Johnson TO, Guo T, Orlowski M, He ZM, Cavallaro CL, Guo J, Oksman A, Gluzman IY, Connelly J, Chelsky D, Goldberg DE, Dolle RE. (1998) Identification of potent inhibitors of Plasmodium falciparum plasmepsin II from an encoded statine combinatorial library. *Bioorg Med Chem Lett*, 8, 2315.
26. Hoffman RV, Tao J. (1997) An Improved Enantiospecific Synthesis of Statine and Statine Analogs via 4-(N,N-Dibenzylamino)-3-keto Esters. *J Org Chem*, 62, 2292.
27. Jones DM, Sueiras-Diaz J, Szelke M, Leckie BJ, Beattie SR, Morton J, Neidle S, Kuroda R. (1997) New renin inhibitors containing novel analogues of statine. *J Pept Res*, 50, 109.
28. Majer P, Collins JR, Gulnik SV, Erickson JW. (1997) Structure-based subsite specificity mapping of human cathepsin D using statine-based inhibitors. *Protein Sci*, 6, 1458.
29. Kroemer RT, Ettmayer P, Hecht P. (1995) 3D-quantitative structure-activity relationships of human immunodeficiency virus type-1 proteinase inhibitors: comparative molecular field analysis of 2-heterosubstituted statine derivatives-implications for the design of novel inhibitors. *J Med Chem*, 38, 4917.
30. Paruszewski R, Jaworski P, Tautt J, Dudkiewicz J. (1994) Enzymatically stable renin inhibitors containing statine and 6 aminohexanoic acid. Part IV. *Boll Chim Farm*, 133, 301.
31. Bailey D, Cooper JB, Veerapandian B, Blundell TL, Atrash B, Jones DM, Szelke M. (1993) X-ray-crystallographic studies of complexes of pepstatin A and a statine-containing human renin inhibitor with endothiapepsin. *Biochem J*, 289 (Pt 2), 363.
32. Hui KY, Hermann RB, Manetta JV, Gygi T, Angleton EL. (1993) Model peptides to study the effects of P2 and P3 substitutions in statine-containing HIV proteinase inhibitors. *FEBS Lett*, 327, 355.
33. Paruszewski R, Tautt J, Dudkiewicz J. (1993) Renin inhibitors containing statine and 6-aminohexanoic acid. Part III. *Pol J Pharmacol*, 45, 75.
34. Sakurai M, Sugano M, Handa H, Komai T, Yagi R, Nishigaki T, Yabe Y. (1993) Studies of HIV-1 protease inhibitors. I. Incorporation of a reduced peptide, simple aminoalcohol, and statine analog at the scissile site of substrate sequences. *Chem Pharm Bull (Tokyo)*, 41, 1369.
35. Fehrentz JA, Chomier B, Bignon E, Venaud S, Chermann JC, Nisato D. (1992) Statine based tripeptides as potent inhibitors of HIV-1 replication. *Biochem Biophys Res Commun*, 188, 873.
36. Fehrentz JA, Chomier B, Bignon E, Venaud S, Chermann JC, Nisato D. (1992) HIV-1 protease inhibitors containing statine: inhibitory potency and antiviral activity. *Biochem Biophys Res Commun*, 188, 865.
37. Suguna K, Padlan EA, Bott R, Boger J, Parris KD, Davies DR. (1992) Structures of complexes of rhizopuspepsin with pepstatin and other statine-containing inhibitors. *Proteins*, 13, 195.

38. Precigoux G. (1991) Conformational preferences and the role of the statine residue in the crystal state. *Biopolymers*, 31, 683.
39. Jupp RA, Dunn BM, Jacobs JW, Vlasuk G, Arcuri KE, Veber DF, Perlow DS, Payne LS, Boger J, de Laszlo S, et al. (1990) The selectivity of statine-based inhibitors against various human aspartic proteinases. *Biochem J*, 265, 871.
40. Nishi T, Saito F, Nagahori H, Kataoka M, Morisawa Y, Yabe Y, Sakurai M, Higashida S, Shoji M, Matsushita Y, et al. (1990) Syntheses and biological activities of renin inhibitors containing statine analogues. *Chem Pharm Bull (Tokyo)*, 38, 103.
41. Roberts DA, Bradbury RH, Brown D, Faull A, Griffiths D, Major JS, Oldham AA, Pearce RJ, Ratcliffe AH, Revill J, et al. (1990) 1,2,4-Triazolo[4,3-a]pyrazine derivatives with human renin inhibitory activity. 1. Synthesis and biological properties of alkyl alcohol and statine derivatives. *J Med Chem*, 33, 2326.
42. Toniolo C, Valle G, Crisma M, Bonora GM, Leij F, Cristinziano PL, Barone V, Nisato D. (1990) Theoretical and experimental conformational analysis of two diastereomeric "Val"-statine derivatives. *Pept Res*, 3, 27.
43. Cooper JB, Foundling SI, Blundell TL, Boger J, Jupp RA, Kay J. (1989) X-ray studies of aspartic proteinase-statine inhibitor complexes. *Biochemistry*, 28, 8596.
44. Maibaum J, Rich DH. (1989) Synthesis of the novel pi-(benzyloxymethyl)-protected histidine analogue of statine. Inhibition of penicillopepsin by pepstatin-derived peptides containing different statine side-chain derivatives. *J Med Chem*, 32, 1571.
45. Goldblum A. (1988) Quantum mechanical modeling of aspartic proteinase interactions: difference in binding of diastereomeric statine models. *Biochem Biophys Res Commun*, 157, 450.
46. Maibaum J, Rich DH. (1988) Inhibition of porcine pepsin by two substrate analogues containing statine. The effect of histidine at the P2 subsite on the inhibition of aspartic proteinases. *J Med Chem*, 31, 625.
47. Bock MG, DiPardo RM, Evans BE, Rittle KE, Boger J, Poe M, LaMont BI, Lynch RJ, Ulm EH, Vlasuk GP, et al. (1987) Renin inhibitors. Statine-containing tetrapeptides with varied hydrophobic carboxy termini. *J Med Chem*, 30, 1853.
48. Kokubu T, Hiwada K, Murakami E, Muneta S, Morisawa Y, Yabe Y, Koike H, Iijima Y. (1987) In vitro inhibition of human renin by statine-containing tripeptide renin inhibitor (ES-1005). *J Cardiovasc Pharmacol*, 10 Suppl 7, S88.
49. Rosenberg SH, Plattner JJ, Woods KW, Stein HH, Marcotte PA, Cohen J, Perun TJ. (1987) Novel renin inhibitors containing analogues of statine retro-inverted at the C-termini: specificity at the P2 histidine site. *J Med Chem*, 30, 1224.
50. Salituro FG, Agarwal N, Hofmann T, Rich DH. (1987) Inhibition of aspartic proteinases by peptides containing lysine and ornithine side-chain analogues of statine. *J Med Chem*, 30, 286.
51. Stammers DK, Dann JG, Harris CJ, Smith DR. (1987) Comparison of angiotensinogen and tetradecapeptide as substrates for human renin. Substrate dependence of the mode of inhibition of renin by a statine-containing hexapeptide. *Arch Biochem Biophys*, 258, 413.
52. Toniolo C, Valle G, Bonora GM, Leij F, Barone V, Fraternali F, Callet G, Wagnon J, Nisato D. (1987) Conformational preferences and self-association modes of two diastereomeric statine derivatives. *Int J Pept Protein Res*, 30, 583.
53. Agarwal NS, Rich DH. (1986) Inhibition of cathepsin D by substrate analogues containing statine and by analogues of pepstatin. *J Med Chem*, 29, 2519.
54. Kokubu T, Hiwada K, Nagae A, Murakami E, Morisawa Y, Yabe Y, Koike H, Iijima Y. (1986) Statine-containing dipeptide and tripeptide inhibitors of human renin. *Hypertension*, 8, II1.
55. Boger J, Payne LS, Perlow DS, Lohr NS, Poe M, Blaine EH, Ulm EH, Schorn TW, LaMont BI, Lin TY, et al. (1985) Renin inhibitors. Syntheses of subnanomolar, competitive, transition-state analogue inhibitors containing a novel analogue of statine. *J Med Chem*, 28, 1779.